http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Amadori, Sergio (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
On the global well-posedness of BV weak solutions to the Kuramoto-Sakaguchi equation
Amadori, D.,Ha, S.Y.,Park, J. Academic Press 2017 Journal of differential equations Vol.262 No.2
<P>The Kuramoto model is a prototype phase model describing the synchronous behavior of weakly coupled limit-cycle oscillators. When the number of oscillators is sufficiently large, the dynamics of Kuramoto ensemble can be effectively approximated by the corresponding mean-field equation, namely 'the Kuramoto-Sakaguchi (KS) equation'. This KS equation is a kind of scalar conservation law with a nonlocal flux function due to the mean-field interactions among oscillators. In this paper, we provide a unique global solvability of bounded variation (BV) weak solutions to the kinetic KS equation for identical oscillators using the method of front-tracking in hyperbolic conservation laws. Moreover, we also show that our BV weak solutions satisfy local-in-time L-1-stability with respect to BV-initial data. For the ensemble of identical Kuramoto oscillators, we explicitly construct an exponentially growing BV weak solution generated from BV perturbation of incoherent state for any positive coupling strength. This implies the nonlinear instability of incoherent state in a positive coupling strength regime. We provide several numerical examples and compare them with our analytical results. (C) 2016 Elsevier Inc. All rights reserved.</P>
-
Guilhot, Francois,Apperley, Jane,Kim, Dong-Wook,Bullorsky, Eduardo O.,Baccarani, Michele,Roboz, Gail J.,Amadori, Sergio,de Souza, Carmino A.,Lipton, Jeffrey H.,Hochhaus, Andreas,Heim, Dominik,Larson, American Society of Hematology 2007 Blood Vol.109 No.10
<B>Abstract</B><P>Treatment options are limited for patients with imatinib-resistant or -intolerant accelerated phase chronic myeloid leukemia (CML-AP). Dasatinib is a novel, potent, oral, multitargeted kinase inhibitor of BCR-ABL and SRC-family kinases that showed marked efficacy in a phase 1 trial of patients with imatinib-resistant CML. Results are presented for 107 patients with CML-AP with imatinib-resistance or -intolerance from a phase 2, open-label study further evaluating dasatinib efficacy and safety. At 8 months' minimum follow-up, 81%, 64%, and 39% of patients achieved overall, major (MaHR), and complete hematologic responses, respectively, whereas 33% and 24% attained major and complete cytogenetic remission. Of 69 patients who achieved MaHR, 7 progressed. Seventy-six percent of patients are estimated to be alive and progression-free at 10 months. Response rates for the 60% of patients with baseline BCR-ABL mutations did not differ from the total population. Dasatinib was well tolerated: most nonhematologic adverse events (AEs) were mild to moderate; no imatinib-intolerant patients discontinued dasatinib because of AEs. Although common (76% of patients with severe neutropenia), cytopenias were manageable through dose modification. In summary, dasatinib induced significant hematologic and cytogenetic responses in patients with imatinib resistance or intolerance, was well tolerated, and may represent a potent new therapeutic option for CML-AP. Further follow-up is warranted. This trial was registered at www.clinicaltrials.gov as #CA180005.</P>
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
